Accessibility Menu
Aytu BioPharma logo

Aytu BioPharma(NASDAQ) AYTU

Market Cap$25.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-97%
1 Year+0%
1 Month+6%
$2.37
+0.42%
+0.01Today
Aytu BioPharma last closing stock price
MetricPriceDate
Last closeUSD 2.382026-08-10
Aytu BioPharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.78%USD 2.252026-08-03
1 month+5.78%USD 2.252026-07-10
3 month+3.48%USD 2.302026-05-12
Year to date-8.46%USD 2.602025-12-31
1 year+0.42%USD 2.372025-08-08
3 year+37.57%USD 1.732023-08-11
5 year-96.9%USD 76.802021-08-11
Since inception-100%USD 4,088,785.052015-04-21

Aytu BioPharma Financials at a Glance

Market Cap

$25.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$56.60M

Net Income (TTM)

-$34.06M

EPS (TTM)

-$4.58

P/E Ratio

-0.51

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$2.37

Volume

30,323.361

Open

$2.33

Previous Close

$2.38

Daily Range

$2.33 - $2.46

52-Week Range

$1.65 - $3.07

Estimated Earnings Date

Sep 22, 2026

AYTU News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aytu BioPharma

Aytu BioPharma makes prescription medicines for children and teens with ADHD. Its products help families manage daily health challenges, like focus and sleep. The company’s treatments are used mainly in the United States by doctors and pharmacies.

Pills, Sprays, and Solutions: What’s in the Aytu Toolbox?

  • ADHD Portfolio (83.4% of revenue in Q1 2025): Medicines for attention deficit hyperactivity disorder in children and teens, including tablets and liquid forms.
  • Fluoride Supplements: Prescription drops and tablets for infants and children with low fluoride intake.
  • Cough and Cold Relief: Prescription syrup for cough and allergy symptoms, used mainly in children.
  • Insomnia Spray: Oral spray for short-term treatment of sleep problems in adults.

Growth Spurts and New Directions

  • Divested Consumer Health business in July 2024 to focus on prescription drugs.
  • Shifted all ADHD product manufacturing to a U.S. contract manufacturer in late 2024.
  • Signed exclusive distribution deals with Medomie (Israel/Palestinian Authority) and Lupin (Canada) in 2024.
  • Expanded ADHD and pediatric product lines through in-licensing and acquisitions since 2015.
  • Ongoing patent litigation to protect ADHD products from generic competition, with trial set for December 2026.

Why Aytu Stands Out (Without the Hype)

Aytu focuses on prescription medicines for children’s health, especially ADHD. Its business model relies on acquiring and commercializing existing drugs, not inventing new ones. The company uses contract manufacturing and exclusive distribution deals to reach more markets and manage costs.

Five Things You Need to Know

  • Net revenue was $18.5 million in Q1 2025, up 32% year-over-year.
  • ADHD products made up 83.4% of Q1 2025 revenue; pediatric products 16.6%.
  • Gross margin was 69% in Q1 2025, down from 74% in Q1 2024.
  • Operating income was $2.4 million in Q1 2025, compared to a $1.6 million loss last year.
  • Cash and cash equivalents were $18.2 million as of March 31, 2025.

Bottom Line

Aytu has narrowed its focus to prescription drugs for children’s health, especially ADHD. The company adapts through partnerships, product acquisitions, and cost management strategies.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

83

CEO

Joshua R. Disbrow, MBA

Website

www.aytubio.com

Headquarters

Denver, CO 80237, US

AYTU Financials

Key Financial Metrics (TTM)

Gross Margin

62.50%

Operating Margin

-26.79%

Net Income Margin

-60.17%

Return on Equity

-148.91%

Return on Capital

-18.68%

Return on Assets

-30.49%

Earnings Yield

-1.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$25.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

10.73M

Volume

30.32K

Avg. Volume

35.27K

Financials (TTM)

Gross Profit

$35.38M

Operating Income

-$15.16M

EBITDA

-$27.33M

Operating Cash Flow

$1.68M

Capital Expenditure

-$34.00K

Free Cash Flow

$1.64M

Cash & ST Invst.

$26.72M

Total Debt

$22.94M

Aytu BioPharma Performance Analysis

Aytu BioPharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 96,669,000N/A
20232023-06-30USD 107,399,00011.1%
20242024-06-30USD 65,183,000-39.3%
20252025-06-30USD 66,382,0001.8%
Aytu BioPharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30-18.0%
Q12025-09-30-8.2%
Q22025-12-319.2%
Q32026-03-31-18.2%
Aytu BioPharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -1,480.11N/A
20232023-06-30USD -5.11-99.7%
20242024-06-30USD -2.86-44.0%
20252025-06-30USD -2.16-24.5%
Aytu BioPharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30-1490.5%
Q12025-09-3097.4%
Q22025-12-31-1258.3%
Q32026-03-3149.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$12.41M

-32.7%

Gross Profit

$6.84M

-46.6%

Gross Margin

55.10%

N/A

Market Cap

$25.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$305.19K

N/A

Employees

83

N/A

Net Income

-$5.62M

-240.7%

EBITDA

-$4.05M

-167.1%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$26.72M

+47.0%

Total Debt

$22.94M

+1.8%

Accounts Receivable

$24.49M

-31.6%

Inventory

$7.46M

-32.5%

Long Term Debt

$10.47M

-0.6%

Short Term Debt

$12.47M

+4.0%

Return on Assets

-30.49%

N/A

Return on Invested Capital

-29.32%

N/A

Free Cash Flow

-$4.18M

+35.9%

Operating Cash Flow

-$4.18M

+35.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TXMDTherapeuticsMD, Inc.
$2.07+0.00%
BFRIBiofrontera Inc.
$1.21-4.72%
OSRHOSR Holdings, Inc.
$0.41-7.31%
EKSOEkso Bionics Holdings, Inc.
$15.90-9.86%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$138.74+0.04%
ACHRArcher Aviation
$6.26+0.12%
NVDANvidia
$217.55-0.03%
INTCIntel
$97.52-0.04%

Questions About AYTU

What is the current price of Aytu BioPharma?

Aytu BioPharma is trading at $2.38 per share.

What is the 52-week range for Aytu BioPharma?

Over the past 52 weeks, Aytu BioPharma has traded between $1.65 and $3.07.

How much debt does Aytu BioPharma have?

As of the most recent reporting period, Aytu BioPharma reported total debt of $22.94M.

How much cash does Aytu BioPharma have on hand?

Aytu BioPharma reported $26.72M in cash and cash equivalents in its most recent financial results.

What is Aytu BioPharma’s dividend yield?

Aytu BioPharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services